Skip to main content
Explore URMC
menu

Jane Larae Liesveld, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Administrative: (585) 275-4099

Office: (585) 275-5823

Fax: (585) 273-1051

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Cancer

Biography

While the doctor-patient relationship is one of potential intensity and privacy, the best patient care comes from teamwork, which values all who contribute to achieving high-quality care with compassion. Providing patients and their families with the knowledge and means to be partners in care is one of my key roles as a physician.

When a patient is diagnosed with a blood cancer or chronic blood condition, it is often the start of a new journey that will be the beginning of great change. Walking with patients through this journey from start to finish, and offering therapy and guidance along the way, is a source of professional and personal satisfaction for me. Hematology/oncology is a field where clinical and basic research can be rapidly applied to improve outcomes and quality of life.

I grew up in the Midwest, but have lived in Rochester since I began my post-doctoral medical training. My association with Strong, the University of Rochester and the people in our community and surrounding areas has enriched my life. I feel privileged to work in such a wonderful environment. I have expertise in novel therapies for acute myeloid leukemia, stem cell mobilization and homing, as well as stem cell transplantation.

Conditions I Treat

- Leukemia, all types
- Myeloproliferative disorders
- Myelodysplastic syndromes
- Multiple myeloma
- Stem cell transplantation

Research

Effects of oxygen metabolites/chemokines on hematopoietic stem cell expansion and preservation.

Effects of hematopoietic growth factors and inhibitors on AML blast proliferation (correlative clinical studies)

Effects of hematopoietic stem cell adhesion on marrow stromal cell cytokine production.

Role of signal transduction inhibition in treatment of acute myelogenous leukemia/myelodysplasia.

Characterization of mobilized peripheral blood stem cells

Credentials

Education

1980
MD | University of Iowa College of Medicine

Post-doctoral Training & Residency

07/01/1988 - 06/30/1989
Research in Hematology Research Fellowship at University of Rochester Medical Center

07/01/1987 - 06/30/1988
Fellowship in Oncology at University of Rochester Medical Center

07/01/1984 - 06/30/1987
Fellowship in Hematology at University of Rochester Medical Center

07/01/1981 - 06/30/1984
Residency in Medicine at University of Rochester Medical Center

07/01/1980 - 06/30/1981
Internship in Medicine at University of Rochester Medical Center

VIEW ALL expand_more

Awards

2009
Gilda's Club of Rochester Jacob Gitelman Award

2007
Hematology-Oncology Fellowship Teaching Award

2005 - 2007
Aplastic Anemia and MDS International Foundation Gordon Forgash Research Award

2004 - 2006
Lawrence A. Kohn Senior Teaching Fellowship
Sponsor: University of Rochester Department of Medicine

1998 - 2003
Leukemia Society of America, Clinical Scholar Award

1989 - 1992
Leukemia Society of America Special Fellowship

1989 - 1992
James P. Wilmot Postdoctoral Cancer Research Fellowship

1987 - 1988
American Cancer Society Clinical Fellowship Award

VIEW ALL expand_more

Clinical Trials

Phase III Randomized Study of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia

Lead Researcher: Jane Larae Liesveld MD

A phase III randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3 mutation. About 510 subjects will be randomized in a 1:1 ratio to receive either crenolanib in addition to standard first line treatment of AML (chemotherapy and if eligible, transplantation) (arm A) or midostaurin and standard treatment (arm B). Potentially eligible subjects will be registered and tested for the presence of FLT3 mutation. Once the FLT3 mutation status is confirmed and additional eligibility is established, subject will be randomized and enter into the treatment phase.

View Study Details

Patents

Patent Title: Continuous Flow Chamber Device for Separation, Concentration and/or Purification of Cells
Patent #: 7,892,766
Issue Date: Feb 22, 2011
Country: United States
Invented By: Nichola Charles, Nathan Clark, John P Gentile, Michael R King, Jane Liesveld, Nipa Anand Mody

Publications

Journal Articles

10/13/2020
Gupta V, Kim S, Hu ZH, Liu Y, Aljurf M, Bacher U, Beitinjaneh A, Cahn JY, Cerny J, Copelan E, Gadalla SM, Gale RP, Ganguly S, George B, Gerds AT, Gergis U, Hamilton BK, Hashmi S, Hildebrandt GC, Kamble RT, Kindwall-Keller T, Lazarus HM, Liesveld JL, Litzow M, Maziarz RT, Nishihori T, Olsson RF, Rizzieri D, Savani BN, Seo S, Solh M, Szer J, Verdonck LF, Wirk B, Woolfrey A, Yared JA, Alyea EP, Popat UR, Sobecks RM, Scott BL, Nakamura R, Saber W. "Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS." Blood advances.. 2020 Oct 13; 4(19):4748-4757.

9/19/2020
Flannelly C, Tan BE, Tan JL, McHugh CM, Sanapala C, Lagu T, Liesveld JL, Aljitawi O, Becker MW, Mendler JH, Klepin HD, Stock W, Wildes TM, Artz A, Majhail NS, Loh KP. "Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2020 Sep 19; Epub 2020 Sep 19.

6/8/2020
Farhadfar N, Murthy HS, Logan BR, Sees JA, Ayas M, Battiwalla M, Beitinjaneh AM, Chhabra S, Diaz MA, Engles K, Frangoul H, Ganguly S, Gergis U, Kamani NR, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Norkin M, O' Donnell PV, Olsson RF, Rossmann S, Savani BN, Schears R, Seo S, Solh MM, Spitzer T, Sugrue M, Yared JA, Linenberger M, Schwartz J, Pulsipher MA, Shah NN, Switzer GE, Confer DL, Shaw BE, Wingard JR. "Correction: Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis." Bone marrow transplantation.. 2020 Jun 8; Epub 2020 Jun 08.

Books & Chapters

2017
Chapter Title: Stem Cell Mobilization
Book Title: In: Encyclopedia of Cancer
Author List: Liesveld, JL
Edited By: Schwab, M
Published By: Springer-Verlag 2017

2016
Chapter Title: Chronic Myelogenous Leukemia and Related Disorders
Book Title: In: Williams Hematology
Author List: Liesveld, JL and Lichtman, MA
Edited By: Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, Caligiuri MA,
Published By: McGraw Hill 2016 in New York, NY

2016
Chapter Title: Acute Myelogenous Leukemia
Book Title: In: Williams Hematology
Author List: Liesveld, JL and Lichtman, MA
Edited By: Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, Caligiuri MA
Published By: McGraw Hill 2016 in New York, NY

VIEW ALL PUBLICATIONS

Videos

play_circle_filled

SECOND OPINION | Leukemia (CLL) | APT

play_circle_filled

SECOND OPINION | Leukemia (CLL) | APT | Full Episode